|
|
|
|
LEADER |
01000caa a22002652 4500 |
001 |
NLM155681311 |
003 |
DE-627 |
005 |
20250206104701.0 |
007 |
tu |
008 |
231223s2005 xx ||||| 00| ||eng c |
028 |
5 |
2 |
|a pubmed25n0519.xml
|
035 |
|
|
|a (DE-627)NLM155681311
|
035 |
|
|
|a (NLM)15925829
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
100 |
1 |
|
|a Kuss, Iris
|e verfasserin
|4 aut
|
245 |
1 |
0 |
|a Recent thymic emigrants and subsets of naive and memory T cells in the circulation of patients with head and neck cancer
|
264 |
|
1 |
|c 2005
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
500 |
|
|
|a Date Completed 09.08.2005
|
500 |
|
|
|a Date Revised 14.11.2007
|
500 |
|
|
|a published: Print
|
500 |
|
|
|a Citation Status MEDLINE
|
520 |
|
|
|a Apoptosis of circulating CD8+ T lymphocytes is a frequent finding in patients with cancer. T-cell output by the thymus or antigen-driven expansion of circulating T cells could compensate for apoptosis and thus normalize their homeostasis. We studied the frequency of recent thymic emigrants (RTE) identified by T-cell receptor excision circles (TREC) and of naive and memory T-cell subsets in peripheral blood samples obtained from 39 patients with head and neck cancer (HNC) and 33 age-matched controls (NC). TREC numbers were determined by real-time quantitative PCR, and CD8+CD45RO-CD27+ or CD4+CD45RO-CD27+ T-cell subsets were quantified by flow cytometry. Age-associated decreases in TREC numbers and proportions of naive CD8+ and CD4+ T-cell subsets were significantly greater in cancer patients than NC. In contrast, the memory compartment was expanded, with increased proportions of CD4+CD45RO+ but not CD8+CD45RO+ T cells, in cancer patients vs. NC. These alterations did not normalize in patients who were NED. The data suggest that lower thymic output combined with rapid turnover of naive CD8+ T cells account for altered lymphocyte homeostasis in HNC patients. The defect persists long after curative treatments and may contribute to immune cell dysregulation in patients with cancer
|
650 |
|
4 |
|a Journal Article
|
650 |
|
4 |
|a Research Support, N.I.H., Extramural
|
650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
650 |
|
4 |
|a Research Support, U.S. Gov't, P.H.S.
|
650 |
|
7 |
|a Receptors, Antigen, T-Cell
|2 NLM
|
700 |
1 |
|
|a Schaefer, Carsten
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Godfrey, Tony E
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Ferris, Robert L
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Harris, Jeffrey M
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Gooding, William
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Whiteside, Theresa L
|e verfasserin
|4 aut
|
773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 116(2005), 1 vom: 30. Juli, Seite 27-36
|w (DE-627)NLM098196855
|x 1521-6616
|7 nnns
|
773 |
1 |
8 |
|g volume:116
|g year:2005
|g number:1
|g day:30
|g month:07
|g pages:27-36
|
912 |
|
|
|a GBV_USEFLAG_A
|
912 |
|
|
|a SYSFLAG_A
|
912 |
|
|
|a GBV_NLM
|
912 |
|
|
|a GBV_ILN_11
|
912 |
|
|
|a GBV_ILN_24
|
912 |
|
|
|a GBV_ILN_350
|
951 |
|
|
|a AR
|
952 |
|
|
|d 116
|j 2005
|e 1
|b 30
|c 07
|h 27-36
|